Apolactoferrin [146897-68-9]

Athens Research

Apolactoferrin [146897-68-9]

9

Iron Transport, Antimicrobial, Inflammation, Immunology

146897-68-9

Research Use Only

≥95% by SDS-PAGE

Lactotransferrin

Apolactoferrin, the iron-free isoform of lactoferrin, retains the iron-binding capacity of its parent protein while exhibiting distinct functional properties. Constituting more then90% of lactoferrin in human milk, this glycoprotein plays critical roles in neonatal immunity and nutrient regulation. Unlike iron-saturated hololactoferrin, apolactoferrin exerts bacteriostatic effects through dual mechanisms: iron sequestration (depriving pathogens of essential nutrients) and direct microbial membrane disruption via cationic peptides like lactoferricin. Its synergy with secretory IgA enhances intestinal barrier function in breastfed infants, inhibiting pathogens such as Escherichia coli and Streptomyces scabiei. Clinically, apolactoferrin contributes to reducing necrotizing enterocolitis (NEC) in preterm infants by modulating gut microbiota and suppressing pro-inflammatory cytokines like TNF-alfa. It also shows promise in managing iron-deficiency anemia, as its iron-free state facilitates dietary iron absorption by competitively binding dietary inhibitors (e.g., phytates)6. Elevated apolactoferrin levels correlate with reduced sepsis risk in neonates, while its anti-amyloid activity in Alzheimer’s models suggests neuroprotective potential716. Therapeutically, apolactoferrin supplements are used for immune support and infection prophylaxis, particularly in formula-fed infants. Emerging applications include adjunct therapy for inflammatory bowel disease and COVID-19, leveraging its cytokine-modulating and antiviral properties.

more then 1 year

Prepared from human milk shown to be non reactive for HBsAg, anti-HCV, anti-HBc, and negative for anti-HIV 1 & 2 by FDA-required tests.

-20C

41116100